News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Predix Pharmaceuticals Pulls IPO, Citing Weak Market
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 26, 2005--Predix Pharmaceuticals announced today that, due to market conditions, it is withdrawing the company's S-1 registration statement from the Securities and Exchange Commission (SEC).
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Immunology and inflammation
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
October 23, 2026
·
1 min read
·
Annalee Armstrong
China
US explores China biotech restrictions, exempts licensing deals
October 23, 2026
·
3 min read
Deals
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
October 23, 2026
·
2 min read
·
Tristan Manalac
IPO
Biotech notches 31 IPOs already this year, with 4 more joining queue
October 22, 2026
·
1 min read
·
Gabrielle Masson
